Healthcare

Experimental Alzheimer’s drug slows cognitive decline in late-stage study

By Abigail Adcox
Published September 28, 2022 3:59pm ET
Add Washington Examiner on Google
Experimental Alzheimer’s drug slows cognitive decline in late-stage study
The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday, Sept. 28, 2022, after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s.

An experimental Alzheimer’s drug made by Eisai Co. and Biogen Inc. slowed the rate of cognitive decline among patients in the early stages of the illness in a large study, improving its chances of future approval.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Alzheimer's Drugs research